No Detail Found!

Clinical nephrotoxicity induced by cyclosporin A combined with hormone therapy for nephrotic syndrome

Author(s)
Xiaoli Liu Affiliated Hospital of Hebei Engineering University,Handan, Hebei,China
Guiying Li Medical College, Hebei University of Engineering,Handan, Hebei,China
Xin Liu Affiliated Hospital of Hebei Engineering University,Handan, Hebei,China
Yansong Huang Handan First Hospital,Handan, Hebei,China
Zhijie Xun Handan First Hospital,Handan, Hebei,China
Qian Song Handan First Hospital,Handan, Hebei,China
Ruixia Wang Handan Second Hospital,Handan, Hebei,China
Congmin Wang Affiliated Hospital of Hebei Engineering University,Handan, Hebei,China
Abstract
This study aims to explore the nephrotoxicity due to use of combination of cyclosporine A and hormone in the treatment of nephrotic syndrome. From January 2018 to November 2019, 100 patients with primary nephrotic syndrome were divided into experimental and control groups, with 50 patients per group. The experimental group took oral cyclosporine A and prednisone tablets, while the control group received oral cyclosporine A combined with shock therapy. The contents of white blood cells, triglycerides, urine protein and cholesterol in the experimental group were lower than those in the control group, while their albumin content was significantly higher than the control values. Blood concentrations of cyclosporine A were significantly lower in non-nephrotoxic patients than in nephrotoxic patients. The high blood cyclosporine A level in patients (>200ng/mL) may be a factor for inducement of nephrotoxicity. Basal serum creatinine levels in nephrotoxic patients were significantly higher than those in non-nephrotoxic patients. Therefore, high basal creatinine level may be a contributing factor to nephrotoxicity. The combination of cyclosporine A and hormone is effective in the treatment of nephrotic syndrome. Blood cyclosporine A levels greater than 200ng/ml or elevated basal serum creatinine may be the cause of nephrotoxicity.
Publication Details
Page(s) 2441-2445
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: S6, Year: 2021

Request the full text from PASTIC

Keywords
combination, Nephrotoxicity, treatment, Clinical observation, Cyclosporine A, Hormones, Nephrotic syndrome
References
Chan TYK,Chan APL,Tang HL .2020 .Nephrotic syndrome caused by exposures to skin-lightening cosmetic products containing inorganic mercury. Clin. Toxicol. (Phila), 58(1) : 9-15.
Downie ML,Gallibois C,Parekh RS,Noone DG .2017 .Nephrotic syndrome in infants and children: pathophysiology and management. Paediatr Int. Child Health, 37(4) : 248-258.
Etta PK,Reddy S,Rao MV,Thatipamula M .2019 .A very rare unexpected fatal complication of nephrotic syndrome. Indian J. Nephrol., 29(6) : 435-437.
Hamasaki Y,Komaki F,Ishikura K,Hamada R,Sakai T,Hataya H,Ogata K,Ando T,Honda M .2017 .Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment. Pediatr Nephrol, 32(8) : 1383-1390.
Hejazian SM,Zununi Vahed S,Moghaddas Sani H,Nariman-Saleh-Fam Z,Bastami M,Hosseiniyan Khatibi SM,Ardalan M,Samadi N M .2020 .Steroidresistant nephrotic syndrome: Pharmacogenetics and epigenetic points and views. Expert Rev Clin Pharmacol., 13(2) : 147-156.
Kondo H,Watanabe R,Okazaki S,Kuriyama K,Ochi T,Yamada G,Sugiura A,Chiba H,Tsukada A,Taniuchi S,Igarashi T,Kudo M,Harigae H,Fujii H H .2020 .JAK2 mutation-positive polycythaemia vera associated with IgA vasculitis and nephrotic syndrome: A case report. Mod. Rheumatol Case Rep., 4, (2) : 289-295.
Lebel A,Kropach N,Ashkenazi-Hoffnung L,HuberYaron A,Davidovits M .2020 .Infections in children with nephrotic syndrome: Twenty years of experience. Clin Pediatr (Phila), 59(7) : 692-698.
Meena J,Sinha A,Hari P,Bagga A .2020 .Therapy with the combination of tolvaptan and furosemide for refractory edema in nephrotic syndrome. Indian J. Nephrol., 30(1) : 53-55.
Mollazadeh S,Sahebkar A,Hadizadeh F,Behravan J,Arabzadeh S J .2018 .Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci, : 214118-123.
Pınarbaşı AS,Dursun I,Daldaban B,Günay N,Çiçek S,Şahin N,Yel S,Poyrazoglu MH,Akgün H,Düşünsel R H .2019 .Epidermolysis bullosa complicated with nephrotic syndrome due to AA amyloidosis: A case report and brief review of literature. Saudi J Kidney Dis Transpl, 30(6) : 1450-1456.
Querfeld U,Weber LT U .2018 .Mycophenolate mofetil for sustained remission in nephrotic syndrome. Pediatr Nephrol, 33(12) : 2253-2265.
Rahman MA,Rahman MH,Karim MR,Huque SS .2019 .Multiple loculated peritoneal abscesses in a child with nephrotic syndrome: A rare presentation. Saudi J Kidney Dis Transpl, 30(6) : 1475-1478.
Rathore V,Bhattacharya D,Pandey J,Bhatia A,Dawman L,Tiewsoh K L .2020 .Chylothorax in a child with nephrotic syndrome. Indian J. Nephrol, 30(1) : 32-34.
Sugimoto K,Miyazawa T,Enya T,Miyazaki K,Okada M,Takemura T .2017 .Cyclosporine A induced histological changes of Cathepsin L and CD2AP expression in renal glomeruli and tubules. Clin. Exp. Nephrol., 21(1) : 83-91.
Yu X,Ruan L,Qu Z,Cui Z,Zhang Y,Wang X,Meng L,Liu X,Wang F,Zhang Y,Liu G,Yang L G .2017 .Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: Effectiveness and renal safety. Ren Fail, 39(1) : 688-697.
0

Citations

0

Downloads

9

Views